# Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers

> **NCT05201690** · PHASE1 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 36 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** VV116 200 mg Group
- **DRUG:** VV116 400mg Group
- **DRUG:** VV116 600mg Group

## Key facts

- **NCT ID:** NCT05201690
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201690, "Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05201690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*